JMDC (4483) Q2 2026 earnings summary

Executive summary

• Revenue for the six months ended September 30, 2025, rose 24.4% year-over-year to ¥23,080 million, with operating profit up 27.7% to ¥4,025 million and EBITDA up 23.3% to ¥5,524 million.

• Healthcare - Big Data segment was the main growth driver, with strong revenue and EBITDA increases year-over-year.

• Tele-medicine segment maintained high profitability and stable growth, supported by steady demand.

• Profit attributable to owners of parent increased 8.5% year-over-year to ¥2,376 million, and basic earnings per share rose to ¥36.35.

• The dispensing pharmacy support business was classified as discontinued operations following the transfer of all shares of NOAH MEDICAL SYSTEM CORPORATION.

Financial highlights

• Consolidated revenue for H1 FY2025 was JPY 23,080 million, up 24% year-over-year.

• Consolidated EBITDA reached JPY 5,524 million, up 23% year-over-year, with a margin of 24%.

• Operating profit was JPY 4,025 million (17% margin), and profit attributable to owners of parent was JPY 2,376 million (10% margin).

• Gross profit increased to ¥12,354 million from ¥10,352 million year-over-year.

• Total assets grew to ¥152,674 million, up from ¥143,020 million as of March 31, 2025.

Outlook and guidance

• Full-year revenue forecast for the fiscal year ending March 31, 2026, is ¥50,500 million, with operating profit of ¥11,500 million and EBITDA of ¥14,500 million.

• Progress against full-year forecasts is on track, with 46% of revenue and 38% of EBITDA targets achieved by H1.

• Basic earnings per share for the full year is projected at ¥113.20.

• No revisions have been made to previously announced earnings forecasts.

• Revenues and profits are expected to be disproportionately focused in H2, with continued vigilance to achieve guidance.